Chaosheng Chen
First Affiliated Hospital of Wenzhou Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chaosheng Chen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:03 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT03123406 · Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPTKyowa Kirin China Pharmaceutical Co., Ltd. · completed · Hyperparathyroidism; Secondary, Renal · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:03 UTC. The ranking covers the 200 most relevant of 2804 PubMed records, and a shared surname and initials can bring in a namesake. All 2804 on PubMed
- 694 citationsRCR 61.8
- 335 citationsRCR 41.3
- 238 citationsRCR 27.5
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.N Engl J Med · 2025175 citationsRCR 63.3
- Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.N Engl J Med · 2024170 citationsRCR 31.0
- 159 citationsRCR 16.8
- Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial.Lancet Respir Med · 2025148 citationsRCR 26.1
- Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.Lancet Gastroenterol Hepatol · 2023102 citationsRCR 9.8
- 90 citationsRCR 15.1
- 78 citationsRCR 9.1